1st Annual Total Cancer Care Summit: The Future of Personalized Medicine (TCC07)
Venue: Atlantis Resort
|Event Date/Time: Oct 24, 2007||End Date/Time: Oct 28, 2007|
|Registration Date: Sep 24, 2007|
|Early Registration Date: Aug 27, 2007|
The First Annual Total Cancer Care Summit will focus on the prospect of developing a one-of-a-kind integrated data repository, pairing molecular and clinical data that will be the mechanism to find the right drug for the right patient. The Summit will bring together experts in multiple disciplines to outline and develop strategies to ultimately deliver personalized health care to the patient by the year 2010. The Summit participants will develop and discuss their vision for radically changing the drug development strategy to a new paradigm whereby patients are selected for each new drug trial rather than being assigned to a new trial based on tumor site alone, without regard to potential target. Conference participants will become thoroughly versed in each of the following topics:
• Drug target identification
• Biobanking and bioinformatics
• Molecular signatures
• Clinical outcomes and quality improvement
• Clinical trials networking
• Population-based trial matching
As a result of this program, participants will be able to:
1. Define the benefits of personalized therapy for human cancers;
2. Describe how genomic signatures contribute to strategies of personalized care;
3. Describe the emerging role of SNPs in predicting response to therapy and drug toxicity;
4. Describe common problems and late effects experienced by cancer survivors and interventions to address these issues;
5. Evaluate methods used to measure quality of cancer care and their implementation in community practice settings;
6. Identify the increasing role of biobanking in cancer research;
7. Discuss the benefits of collaboration with industry in the field of personalized medicine.
This educational activity is planned to meet the educational needs of principal and clinical investigators, as well as clinical and surgical oncologists in both academia and industry Students specialized in cancer research and innovation are also encouraged to attend.
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of South Florida College of Medicine and H. Lee Moffitt Cancer Center & Research Institute. The University of South Florida College of Medicine is accredited by the ACCME to provide continuing medical education for physicians. The University of South Florida College of Medicine designates this educational activity for a maximum of 16 AMA PRA Category 1 CreditsTM.
For more information on the conference, please visit our website at www.moffitt.org/continuinged/tcc or contact Elizabeth Dackson, Conference Coordinator, at Elizabeth.Dackson@Moffitt.org